FAM193B Antibody | 6941

FAM193B Antibody | 6941 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Bovine: (100%) , Mouse: (81%)

Immunogen: FAM193B antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human FAM193B.
The immunogen is located within amino acids 120 - 170 of FAM193B.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB, IF

Application: FAM193B antibody can be used for detection of FAM193B by Western blot at 1 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: At least two isoforms of FAM193B are known to exist; this antibody will detect both isoforms.

Positive Control 1: Cat. No. 1205 - Jurkat Cell Lysate

Positive Control 2: Cat. No. 17-005 - Jurkat Cell Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 99 kDa

Validation: N/A

Isoform: N/A

Purification: FAM193B Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: FAM193B Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: FAM193B antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: FAM193B Antibody: IRIZIO, KIAA1931, Protein FAM193B

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: FAM193B Antibody: FAM193B, also known as IRIZIO, was initially identified as a protein that is upregulated in alveolar rhabdomyosarcoma (ARMS) , a type of fast-growing tumor characterized by chromosomal translocations fusing the PAX3 or PAX7 gene with that of FOXO1. It has been suggested that, in addition to the PAX3-FOXO1 gene fusion, disruption of the Rb and p53 pathways is required for full ARMS tumorigenesis. In PAX3-FOXO1-expressing primary mouse fibroblasts that possessed a defective p53 pathway, FAM193B expression enabled the tumorigenic transformation, suggesting that FAM193B may contribute to rhabdomyosarcomagenesis in humans.